Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Agnes M. Gawne"'
Autor:
Heather H. Cheng, Michael T. Schweizer, Daniel M. Lim, Evan Y. Yu, Rigo I. Acevedo, Agnes M. Gawne, R. Bruce Montgomery, Alexander S. Carlson, Alexandra O. Sokolova, Roman Gulati, Peter S. Nelson
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239686 (2020)
PLoS ONE
PLoS ONE
IntroductionA significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility
Autor:
Ruth Etzioni, Daniel M. Lim, Serge Aleshin-Guendel, Jonathan T. Wingate, Heather H. Cheng, Roman Gulati, Agnes M. Gawne, Evan Y. Yu
Publikováno v:
The Prostate. 78:1077-1083
BACKGROUND Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate-specific antigen (PSA) levels as a marker of efficac
Autor:
Daniel M. Lim, Heather H. Cheng, Ruth Etzioni, Jonathan T. Wingate, Evan Y. Yu, Serge Aleshin-Guendel, Agnes M. Gawne, Roman Gulati
Publikováno v:
Journal of Clinical Oncology. 36:e17073-e17073
e17073Background: Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Durable undetectable prostate-specific antigen ...
Autor:
Jonathan T. Wingate, Roman Gulati, Ruth Etzioni, Agnes M. Gawne, Heather H. Cheng, Serge Aleshin-Guendel, Evan Y. Yu, Daniel M. Lim
Publikováno v:
Journal of Clinical Oncology. 36:207-207
207 Background: Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate specific antigen (PSA) levels as a marker of ef